** Biocon BION.NS drops ~5% and is the top pct loser on
Nifty pharma index .NIPHARM , which is down 1.5%
** BION shares rose 5.8% on Thurs on saying unit Biocon
Biologics will sell its branded formulations business to Eris
Lifesciences ERIS.NS for 12.42 bln rupees ($150 mln)
** Brokerage Kotak says the deal value was below its
expectations; keeps "reduce" rating"
** Eris stock down 2.5%, after gaining 3.8% on Thurs
** Kotak says despite ~10% drop in net debt post deal,
BION's leverage (net debt to EBITDA at 2.8X even in FY26)
remains a key concern
** Avg rating of 17 analysts on BION is "hold" -LSEG data
(Reporting by Kashish Tandon in Bengaluru)
((kashish.tandon@thomsonreuters.com))